SlideShare ist ein Scribd-Unternehmen logo
1 von 25
 
Contenido y Distribución del Calcio, Fosfato y Magnesio 40 % 60 % 22-25 g Magnesio 15-20% 80-85% 600-6500g Fosfato 1-2% 98-99% 1000-1200 g Calcio % extraoseo % en hueso Total corporal
Funciones Fisiológicas del Calcio ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Calmodulina ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
Glándula Paratiriodea - Parathormona ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Colecalciferol (Vitamina D3) 25-hidroxicolecalciferol 1,25-dihidroxicolecalciferol Prot. unión calcio ATPasa dependiente de calcio Fosfatasa alcalina Absorción Ca++ Hormona  paratiroidea activación inhibición inhibición Higado
Figure 24-24 Parathyroid adenomas are almost always solitary lesions. Technetium-99m-sestamibi radionuclide scan demonstrates an area of increased uptake corresponding to the leftinferior parathyroid gland  (arrow) . This patient had a parathyroid adenoma. Preoperative scintigraphy is useful in localizing and distinguishing adenomas from parathyroid hyperplasia, where more than one gland would demonstrate increased uptake.
 
HIPERPARATIROIDISMO PRIMARIO  :  PROBLEMA EN LA GLÁNDULA. INDEPENDIENTE DE LOS NIVELES DE CALCIO CIRCULANTE. HABITUALMENTE . CURSA CON HIPERCALCEMIA SECUNDARIO  :  RESPUESTA A UNA DISMINUCIÓN PERSISTENTE DE CALCEMIA ( INSUF RENAL, ETC). Con el tiempo puede hacerse autónomo, independiente del calcio
Figure 24-26 Cardinal features of hyperparathyroidism. With routine evaluation of calcium levels in most patients, primary hyperparathyroidism is often detected at a clinically silent stage. Hypercalcemia from any other cause can also give rise to the same symptoms.
HIPOPARATIROIDISMO El hipoparatiroidismo  produce  hipocalcemia La hipocalcemia aguda produce un aumento de la excitabilidad neuromuscular  El aumento de la excitabilidad neuromuscular de cualquier causa se llama TETANIA
Hipocalcemia
 
Figure 24-27 Hormone production in pancreatic islet cells. Immunoperoxidase staining shows a dark reaction product for insulin in b cells (A), glucagon in a cells (B), and somatostatin in d cells (C). D, Electron micrograph of a b cell shows the characteristic membrane-bound granules, each containing a dense, often rectangular core and distinct halo. E, Portions of an a cell (left) and a d cell (right) also exhibit granules, but with closely apportioned membranes. The a-cell granule exhibits a dense, round center. (Electron micrographs courtesy of Dr. A. Like, University of Massachusetts Medical School, Worcester, MA.)
Figure 24-28 Insulin synthesis and secretion. Intracellular transport of glucose is mediated by GLUT-2, an insulin-independent glucose transporter in b cells. Glucose undergoes oxidative metabolism in the b cell to yield ATP. ATP inhibits an inward rectifying potassium channel receptor on the b-cell surface; the receptor itself is a dimeric complex of the sulfonylurea receptor and a K+ -channel protein. Inhibition of this receptor leads to membrane depolarization, influx of Ca2+ ions, and release of stored insulin from b cells. Figure 24-29 Metabolic actions of insulin in striated muscle, adipose tissue, and liver.
Figure 24-30 Insulin action on a target cell. Insulin binds to the a subunit of insulin receptor, leading to activation of the kinase activity in the b-subunit, and sets in motion a phosphorylation (i.e., activation) cascade of multiple downstream target proteins. The mitogenic functions of insulin (and the related insulin-like growth factors) are mediated via the mitogen-activated protein kinase (MAP kinase) pathway. The metabolic actions of insulin are mediated primarily by activation of the phosphatidylinositol-3-kinase (PI-3K) pathway. The PI-3K-signaling pathway is responsible for a variety of effects on target cells, including translocation of GLUT-4 containing vesicles to the surface; increasing GLUT-4 density on the membrane and rate of glucose influx; promoting glycogen synthesis via activation of glycogen synthase; and promoting protein synthesis and lipogenesis, while inhibiting lipolysis. The PI-3K pathway also promotes cell survival and proliferation.
TABLE 24-6 -- Classification of Diabetes Mellitus •••••• Neoplasia •••••• Cystic fibrosis •••••• Hemachromatosis •••••• Fibrocalculous pancreatopathy •••••• Pancreatectomy •••••• Chronic pancreatitis • 5. Exocrine pancreatic defects •••••• Insulin receptor mutations •••••• Insulin gene mutations •••••• Defects in proinsulin conversion • 4. Genetic defects in insulin processing or insulin action •••••• Mitochondrial DNA mutations ••••••• Neurogenic differentiation factor 1 [Neuro D1] (MODY6) ••••••• Hepatocyte nuclear factor 1b [HNF-1b] (MODY5) ••••••• Insulin promoter factor [IPF-1] (MODY4) ••••••• Hepatocyte nuclear factor 1a [HNF-1a] (MODY3) ••••••• Glucokinase (MODY2) ••••••• Hepatocyte nuclear factor 4a [HNF-4a] (MODY1) •••••• Maturity-onset diabetes of the young (MODY), caused by mutations in: • 3. Genetic defects of  b -cell function • 2. Type 2 diabetes  (insulin resistance with relative insulin deficiency) •••••• Idiopathic •••••• Immune-mediated • 1. Type 1 diabetes  (b-cell destruction, leads to absolute insulin deficiency)
Data from the Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetic Care 25 (suppl. 1):S5–S20, 2002. 10. Gestational diabetes mellitus •••••• Turner syndrome •••••• Kleinfelter syndrome •••••• Down syndrome • 9. Genetic syndromes associated with diabetes •••••• Phenytoin •••••• Nicotinic acid •••••• Thiazides •••••• b-adrenergic agonists •••••• Protease inhibitors •••••• a-interferon •••••• Thyroid hormone •••••• Glucocorticoids • 8. Drugs •••••• Coxsackie virus B •••••• Cytomegalovirus • 7. Infections •••••• Glucagonoma •••••• Pheochromocytoma •••••• Hyperthyroidism •••••• Cushing syndrome •••••• Acromegaly • 6. Endocrinopathies
Figure 24-31 Stages in the development of type 1 diabetes mellitus. The stages are listed from left to right, and hypothetical b-cell mass is plotted against age.  (From Eisenbarth GE: Type 1 diabetes: a chronic autoimmune disease. N Engl J Med 314:1360, 1986. Copyright © 1986, Massachusetts Medical Society. All rights reserved.)
Figure 24-33 Obesity and insulin resistance: the missing links? Adipocytes release a variety of factors (free fatty acids and adipokines) that may play a role in modulating insulin resistance in peripheral tissues (illustrated here is striated muscle). Excess free fatty acids (FFAs) and resistin are associated with insulin resistance; in contrast, adiponectin, whose levels are decreased in obesity, is an insulin-sensitizing adipokine. Leptin is also an insulin-sensitizing agent, but it acts via central receptors (in the hypothalamus). The peroxisome proliferator-activated receptor gamma (PPARg) is an adipocyte nuclear receptor that is activated by a class of insulin-sensitizing drugs called thiazolidinediones (TZDs). The mechanism of action of TZDs may eventually be mediated through modulation of adipokine and FFA levels that favor a state of insulin sensitivity.
Figure 24-34 Long-term complications of diabetes.
Figure 24-40 Sequence of metabolic derangements leading to diabetic coma in type 1 diabetes mellitus. An absolute insulin deficiency leads to a catabolic state, eventuating in ketoacidosis and severe volume depletion. These cause sufficient central nervous system compromise to lead to coma and eventual death if left untreated.
TABLE 24-8 -- Type 1 Versus Type 2 Diabetes Mellitus (DM) Mild b-cell depletion b-cell depletion atrophy and amyloid deposition Marked atrophy and fibrosis Focal No insulitis Insulitis early Islet cells Absolute insulin deficiency b-cell dysfunction and relative insulin deficiency Insulin resistance in skeletal muscle, adipose tissue and liver Autoimmune destruction of b-cells mediated by T cells and humoral mediators (TNF, IL-1, NO) Pathogenesis Linkage to candidate diabetogenic genes (PPARg, calpain 10) No HLA linkage Linkage to MHC Class II HLA genes 50–90% concordance in twins 30–70% concordance in twins Genetics Ketoacidosis rare; nonketotic hyperosmolar coma Ketoacidosis common No anti-islet cell antibodies Anti-islet cell antibodies Increased blood insulin early); normal to moderate decreased insulin (late) Markedly decreased blood insulin Obese Normal weight Onset: >30 years <20 years Clinical Onset: Type 2 DM Type 1 DM

Weitere ähnliche Inhalte

Was ist angesagt?

Insulin Resistance
Insulin ResistanceInsulin Resistance
Insulin Resistancedrmisbah83
 
The Role of Adiponectin in Obesity and its Clinical Utility in Obesity-Associ...
The Role of Adiponectin in Obesity and its Clinical Utility in Obesity-Associ...The Role of Adiponectin in Obesity and its Clinical Utility in Obesity-Associ...
The Role of Adiponectin in Obesity and its Clinical Utility in Obesity-Associ...Randox Reagents
 
The endocrine system 980218
The endocrine system 980218The endocrine system 980218
The endocrine system 980218talaeizavareh
 
The endocrine system
The endocrine systemThe endocrine system
The endocrine systemRyma Chohan
 
The relationship between serum albumin concentration and sarcopenia
The relationship between serum albumin concentration and sarcopeniaThe relationship between serum albumin concentration and sarcopenia
The relationship between serum albumin concentration and sarcopenia柏毅 楊
 
Insulin and its mechanism of action
Insulin and its mechanism of actionInsulin and its mechanism of action
Insulin and its mechanism of actionAshmita Chaudhuri
 
Cpeptide &amp; diabetes dda 2015
Cpeptide  &amp;  diabetes   dda 2015Cpeptide  &amp;  diabetes   dda 2015
Cpeptide &amp; diabetes dda 2015alaa wafa
 
biochemistry- Role of insulin in metabolism- PHYSIOLOGICAL ACTION OF INSULIN
biochemistry- Role of insulin in metabolism- PHYSIOLOGICAL ACTION OF INSULINbiochemistry- Role of insulin in metabolism- PHYSIOLOGICAL ACTION OF INSULIN
biochemistry- Role of insulin in metabolism- PHYSIOLOGICAL ACTION OF INSULINSaachiGupta4
 
Adipose tissue as an endocrine organ
Adipose tissue as an endocrine organAdipose tissue as an endocrine organ
Adipose tissue as an endocrine organaaronpaulbaliga
 
PP-01: Role of Plasma Proteins in Health and diseases
PP-01: Role of Plasma Proteins in Health and diseasesPP-01: Role of Plasma Proteins in Health and diseases
PP-01: Role of Plasma Proteins in Health and diseasesDr. Santhosh Kumar. N
 
Disorders of lipid metabolism case studies-1
Disorders of lipid metabolism  case studies-1Disorders of lipid metabolism  case studies-1
Disorders of lipid metabolism case studies-1Namrata Chhabra
 
GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES YESANNA
 

Was ist angesagt? (20)

Insulin Resistance
Insulin ResistanceInsulin Resistance
Insulin Resistance
 
Plasma protein
Plasma proteinPlasma protein
Plasma protein
 
The Role of Adiponectin in Obesity and its Clinical Utility in Obesity-Associ...
The Role of Adiponectin in Obesity and its Clinical Utility in Obesity-Associ...The Role of Adiponectin in Obesity and its Clinical Utility in Obesity-Associ...
The Role of Adiponectin in Obesity and its Clinical Utility in Obesity-Associ...
 
Endocrine pancreas
Endocrine pancreasEndocrine pancreas
Endocrine pancreas
 
Disorders of lipid metabolism
Disorders of lipid metabolismDisorders of lipid metabolism
Disorders of lipid metabolism
 
The endocrine system 980218
The endocrine system 980218The endocrine system 980218
The endocrine system 980218
 
The endocrine system
The endocrine systemThe endocrine system
The endocrine system
 
The relationship between serum albumin concentration and sarcopenia
The relationship between serum albumin concentration and sarcopeniaThe relationship between serum albumin concentration and sarcopenia
The relationship between serum albumin concentration and sarcopenia
 
Plasma protein
Plasma proteinPlasma protein
Plasma protein
 
Insulin and its mechanism of action
Insulin and its mechanism of actionInsulin and its mechanism of action
Insulin and its mechanism of action
 
Obesity and inflammation
Obesity and inflammationObesity and inflammation
Obesity and inflammation
 
Cpeptide &amp; diabetes dda 2015
Cpeptide  &amp;  diabetes   dda 2015Cpeptide  &amp;  diabetes   dda 2015
Cpeptide &amp; diabetes dda 2015
 
biochemistry- Role of insulin in metabolism- PHYSIOLOGICAL ACTION OF INSULIN
biochemistry- Role of insulin in metabolism- PHYSIOLOGICAL ACTION OF INSULINbiochemistry- Role of insulin in metabolism- PHYSIOLOGICAL ACTION OF INSULIN
biochemistry- Role of insulin in metabolism- PHYSIOLOGICAL ACTION OF INSULIN
 
Insulin
InsulinInsulin
Insulin
 
Adipose tissue as an endocrine organ
Adipose tissue as an endocrine organAdipose tissue as an endocrine organ
Adipose tissue as an endocrine organ
 
PP-01: Role of Plasma Proteins in Health and diseases
PP-01: Role of Plasma Proteins in Health and diseasesPP-01: Role of Plasma Proteins in Health and diseases
PP-01: Role of Plasma Proteins in Health and diseases
 
Pathophis of carbohydrates and lipids metabolism
Pathophis of carbohydrates and lipids metabolismPathophis of carbohydrates and lipids metabolism
Pathophis of carbohydrates and lipids metabolism
 
Plasma proteins
Plasma proteinsPlasma proteins
Plasma proteins
 
Disorders of lipid metabolism case studies-1
Disorders of lipid metabolism  case studies-1Disorders of lipid metabolism  case studies-1
Disorders of lipid metabolism case studies-1
 
GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES
 

Andere mochten auch

Andere mochten auch (6)

Sistema endócrino pablo
Sistema endócrino pabloSistema endócrino pablo
Sistema endócrino pablo
 
Psicofisiologia 4to trimestre
Psicofisiologia 4to trimestrePsicofisiologia 4to trimestre
Psicofisiologia 4to trimestre
 
Disturbios puerperais
Disturbios puerperaisDisturbios puerperais
Disturbios puerperais
 
Aula hipófise
Aula hipófiseAula hipófise
Aula hipófise
 
Sistema endocrino y funciones
Sistema endocrino y funcionesSistema endocrino y funciones
Sistema endocrino y funciones
 
El Sistema Endocrino y la Conducta
El Sistema Endocrino y la ConductaEl Sistema Endocrino y la Conducta
El Sistema Endocrino y la Conducta
 

Ähnlich wie 04 Cat. Sistema Endocrino II

DIABETES MELLITUS.pptx
DIABETES MELLITUS.pptxDIABETES MELLITUS.pptx
DIABETES MELLITUS.pptxHarrisonMbohe
 
Diabetes Mellitus_230826_193537.pdf detail
Diabetes Mellitus_230826_193537.pdf detailDiabetes Mellitus_230826_193537.pdf detail
Diabetes Mellitus_230826_193537.pdf detailOmpriyaS
 
Anti diabeticdrugs
Anti diabeticdrugsAnti diabeticdrugs
Anti diabeticdrugsDaniel Wang
 
Corticosteroides Mdpm 408
Corticosteroides Mdpm 408Corticosteroides Mdpm 408
Corticosteroides Mdpm 408abjdiat
 
Influence of systemic diseases on periodontium.
Influence of systemic diseases on periodontium.Influence of systemic diseases on periodontium.
Influence of systemic diseases on periodontium.Raveena Bhanushali
 
Diabetic Retinopathy
Diabetic RetinopathyDiabetic Retinopathy
Diabetic Retinopathyerameshita
 
Mitochondrial dynamics and cancer (2)
Mitochondrial dynamics and cancer (2)Mitochondrial dynamics and cancer (2)
Mitochondrial dynamics and cancer (2)soumik1997
 
retinopatrhydiabetic-211003134714 (2).pptx
retinopatrhydiabetic-211003134714 (2).pptxretinopatrhydiabetic-211003134714 (2).pptx
retinopatrhydiabetic-211003134714 (2).pptxNasrinsultanarmc
 
retinopatrhydiabetic-211003134714 (2).pptx
retinopatrhydiabetic-211003134714 (2).pptxretinopatrhydiabetic-211003134714 (2).pptx
retinopatrhydiabetic-211003134714 (2).pptxNasrinsultanarmc
 
Antidiabetic drugs.ppt
Antidiabetic drugs.pptAntidiabetic drugs.ppt
Antidiabetic drugs.pptEl Foro
 
Current concept in the development of diabetes and its classification
Current concept in the development of diabetes and its classificationCurrent concept in the development of diabetes and its classification
Current concept in the development of diabetes and its classificationSaptaparni Hazra
 

Ähnlich wie 04 Cat. Sistema Endocrino II (20)

DIABETES MELLITUS.pptx
DIABETES MELLITUS.pptxDIABETES MELLITUS.pptx
DIABETES MELLITUS.pptx
 
DM.pptx
DM.pptxDM.pptx
DM.pptx
 
Diabetes Mellitus_230826_193537.pdf detail
Diabetes Mellitus_230826_193537.pdf detailDiabetes Mellitus_230826_193537.pdf detail
Diabetes Mellitus_230826_193537.pdf detail
 
Pathogenesis DM
Pathogenesis DM Pathogenesis DM
Pathogenesis DM
 
Pancreas.ppt
Pancreas.pptPancreas.ppt
Pancreas.ppt
 
Anti diabeticdrugs
Anti diabeticdrugsAnti diabeticdrugs
Anti diabeticdrugs
 
Corticosteroides Mdpm 408
Corticosteroides Mdpm 408Corticosteroides Mdpm 408
Corticosteroides Mdpm 408
 
Influence of systemic diseases on periodontium.
Influence of systemic diseases on periodontium.Influence of systemic diseases on periodontium.
Influence of systemic diseases on periodontium.
 
DIABETES MELLITUS-1.pptx
DIABETES MELLITUS-1.pptxDIABETES MELLITUS-1.pptx
DIABETES MELLITUS-1.pptx
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
DM,im 06.ppt
DM,im 06.pptDM,im 06.ppt
DM,im 06.ppt
 
Diabetic Retinopathy
Diabetic RetinopathyDiabetic Retinopathy
Diabetic Retinopathy
 
Complications of diabetes
Complications of diabetes Complications of diabetes
Complications of diabetes
 
Mitochondrial dynamics and cancer (2)
Mitochondrial dynamics and cancer (2)Mitochondrial dynamics and cancer (2)
Mitochondrial dynamics and cancer (2)
 
retinopatrhydiabetic-211003134714 (2).pptx
retinopatrhydiabetic-211003134714 (2).pptxretinopatrhydiabetic-211003134714 (2).pptx
retinopatrhydiabetic-211003134714 (2).pptx
 
retinopatrhydiabetic-211003134714 (2).pptx
retinopatrhydiabetic-211003134714 (2).pptxretinopatrhydiabetic-211003134714 (2).pptx
retinopatrhydiabetic-211003134714 (2).pptx
 
Antidiabetic drugs.ppt
Antidiabetic drugs.pptAntidiabetic drugs.ppt
Antidiabetic drugs.ppt
 
Current concept in the development of diabetes and its classification
Current concept in the development of diabetes and its classificationCurrent concept in the development of diabetes and its classification
Current concept in the development of diabetes and its classification
 
Diabetes mellitus. 2
Diabetes mellitus.  2Diabetes mellitus.  2
Diabetes mellitus. 2
 
Glimepiride
GlimepirideGlimepiride
Glimepiride
 

Mehr von unab.patologia

02 Disert. Mecanismo - Factores y receptores de Crecimiento
02 Disert. Mecanismo - Factores y receptores de Crecimiento02 Disert. Mecanismo - Factores y receptores de Crecimiento
02 Disert. Mecanismo - Factores y receptores de Crecimientounab.patologia
 
07 Disert. Neumonia - Tuberculosis
07 Disert. Neumonia - Tuberculosis07 Disert. Neumonia - Tuberculosis
07 Disert. Neumonia - Tuberculosisunab.patologia
 
07 Disert. Enfermedades Intersticiales
07 Disert. Enfermedades Intersticiales07 Disert. Enfermedades Intersticiales
07 Disert. Enfermedades Intersticialesunab.patologia
 
07 Cat. Sistema Respiratorio
07 Cat. Sistema Respiratorio07 Cat. Sistema Respiratorio
07 Cat. Sistema Respiratoriounab.patologia
 
06 Disert. Tumores Vasculares
06 Disert. Tumores Vasculares06 Disert. Tumores Vasculares
06 Disert. Tumores Vascularesunab.patologia
 
06 Cat. Cardiovascular II
06 Cat. Cardiovascular II06 Cat. Cardiovascular II
06 Cat. Cardiovascular IIunab.patologia
 
05 Disert. Factores Congenitos
05 Disert. Factores Congenitos05 Disert. Factores Congenitos
05 Disert. Factores Congenitosunab.patologia
 
05 Cat. Cardiovascular I
05 Cat. Cardiovascular I05 Cat. Cardiovascular I
05 Cat. Cardiovascular Iunab.patologia
 
05 Disert. Arritmias Cardiacas
05 Disert. Arritmias Cardiacas05 Disert. Arritmias Cardiacas
05 Disert. Arritmias Cardiacasunab.patologia
 
04 Disert. Diabetes Mellitus Tipo II
04 Disert. Diabetes Mellitus Tipo II04 Disert. Diabetes Mellitus Tipo II
04 Disert. Diabetes Mellitus Tipo IIunab.patologia
 
04 Disert. Diabetes Mellitus Tipo I
04 Disert. Diabetes Mellitus Tipo I04 Disert. Diabetes Mellitus Tipo I
04 Disert. Diabetes Mellitus Tipo Iunab.patologia
 
03 Disert. Enfermedad de Cushing
03 Disert. Enfermedad de Cushing03 Disert. Enfermedad de Cushing
03 Disert. Enfermedad de Cushingunab.patologia
 
03 Disert. Enfermedad de Addison
03 Disert. Enfermedad de Addison03 Disert. Enfermedad de Addison
03 Disert. Enfermedad de Addisonunab.patologia
 
03 Cat. Sistema Endocrino I
03 Cat. Sistema Endocrino I03 Cat. Sistema Endocrino I
03 Cat. Sistema Endocrino Iunab.patologia
 
01 Disert. Mediadores quimicos
01 Disert. Mediadores quimicos01 Disert. Mediadores quimicos
01 Disert. Mediadores quimicosunab.patologia
 
01 Disert. Cascada del complemento y citoquinas
01 Disert. Cascada del complemento y citoquinas01 Disert. Cascada del complemento y citoquinas
01 Disert. Cascada del complemento y citoquinasunab.patologia
 

Mehr von unab.patologia (20)

02 Disert. Mecanismo - Factores y receptores de Crecimiento
02 Disert. Mecanismo - Factores y receptores de Crecimiento02 Disert. Mecanismo - Factores y receptores de Crecimiento
02 Disert. Mecanismo - Factores y receptores de Crecimiento
 
07 Disert. Neumonia - Tuberculosis
07 Disert. Neumonia - Tuberculosis07 Disert. Neumonia - Tuberculosis
07 Disert. Neumonia - Tuberculosis
 
07 Disert. Enfermedades Intersticiales
07 Disert. Enfermedades Intersticiales07 Disert. Enfermedades Intersticiales
07 Disert. Enfermedades Intersticiales
 
07 Cat. Sistema Respiratorio
07 Cat. Sistema Respiratorio07 Cat. Sistema Respiratorio
07 Cat. Sistema Respiratorio
 
06 Disert. Vasculitis
06 Disert. Vasculitis06 Disert. Vasculitis
06 Disert. Vasculitis
 
06 Disert. Tumores Vasculares
06 Disert. Tumores Vasculares06 Disert. Tumores Vasculares
06 Disert. Tumores Vasculares
 
06 Cat. Cardiovascular II
06 Cat. Cardiovascular II06 Cat. Cardiovascular II
06 Cat. Cardiovascular II
 
05 Disert. Factores Congenitos
05 Disert. Factores Congenitos05 Disert. Factores Congenitos
05 Disert. Factores Congenitos
 
05 Cat. Cardiovascular I
05 Cat. Cardiovascular I05 Cat. Cardiovascular I
05 Cat. Cardiovascular I
 
05 Disert. Arritmias Cardiacas
05 Disert. Arritmias Cardiacas05 Disert. Arritmias Cardiacas
05 Disert. Arritmias Cardiacas
 
04 Disert. Diabetes Mellitus Tipo II
04 Disert. Diabetes Mellitus Tipo II04 Disert. Diabetes Mellitus Tipo II
04 Disert. Diabetes Mellitus Tipo II
 
04 Disert. Diabetes Mellitus Tipo I
04 Disert. Diabetes Mellitus Tipo I04 Disert. Diabetes Mellitus Tipo I
04 Disert. Diabetes Mellitus Tipo I
 
03 Disert. Enfermedad de Cushing
03 Disert. Enfermedad de Cushing03 Disert. Enfermedad de Cushing
03 Disert. Enfermedad de Cushing
 
03 Disert. Enfermedad de Addison
03 Disert. Enfermedad de Addison03 Disert. Enfermedad de Addison
03 Disert. Enfermedad de Addison
 
03 Cat. Sistema Endocrino I
03 Cat. Sistema Endocrino I03 Cat. Sistema Endocrino I
03 Cat. Sistema Endocrino I
 
02 Cat. Neoplasia
02 Cat. Neoplasia02 Cat. Neoplasia
02 Cat. Neoplasia
 
02 Disert. Oncogenes
02 Disert. Oncogenes02 Disert. Oncogenes
02 Disert. Oncogenes
 
01 Disert. Mediadores quimicos
01 Disert. Mediadores quimicos01 Disert. Mediadores quimicos
01 Disert. Mediadores quimicos
 
01 Disert. Cascada del complemento y citoquinas
01 Disert. Cascada del complemento y citoquinas01 Disert. Cascada del complemento y citoquinas
01 Disert. Cascada del complemento y citoquinas
 
01 Cat. Inflamacion
01 Cat. Inflamacion01 Cat. Inflamacion
01 Cat. Inflamacion
 

04 Cat. Sistema Endocrino II

  • 1.  
  • 2. Contenido y Distribución del Calcio, Fosfato y Magnesio 40 % 60 % 22-25 g Magnesio 15-20% 80-85% 600-6500g Fosfato 1-2% 98-99% 1000-1200 g Calcio % extraoseo % en hueso Total corporal
  • 3.
  • 4.
  • 5.
  • 6.  
  • 7.
  • 8. Colecalciferol (Vitamina D3) 25-hidroxicolecalciferol 1,25-dihidroxicolecalciferol Prot. unión calcio ATPasa dependiente de calcio Fosfatasa alcalina Absorción Ca++ Hormona paratiroidea activación inhibición inhibición Higado
  • 9. Figure 24-24 Parathyroid adenomas are almost always solitary lesions. Technetium-99m-sestamibi radionuclide scan demonstrates an area of increased uptake corresponding to the leftinferior parathyroid gland (arrow) . This patient had a parathyroid adenoma. Preoperative scintigraphy is useful in localizing and distinguishing adenomas from parathyroid hyperplasia, where more than one gland would demonstrate increased uptake.
  • 10.  
  • 11. HIPERPARATIROIDISMO PRIMARIO : PROBLEMA EN LA GLÁNDULA. INDEPENDIENTE DE LOS NIVELES DE CALCIO CIRCULANTE. HABITUALMENTE . CURSA CON HIPERCALCEMIA SECUNDARIO : RESPUESTA A UNA DISMINUCIÓN PERSISTENTE DE CALCEMIA ( INSUF RENAL, ETC). Con el tiempo puede hacerse autónomo, independiente del calcio
  • 12. Figure 24-26 Cardinal features of hyperparathyroidism. With routine evaluation of calcium levels in most patients, primary hyperparathyroidism is often detected at a clinically silent stage. Hypercalcemia from any other cause can also give rise to the same symptoms.
  • 13. HIPOPARATIROIDISMO El hipoparatiroidismo produce hipocalcemia La hipocalcemia aguda produce un aumento de la excitabilidad neuromuscular El aumento de la excitabilidad neuromuscular de cualquier causa se llama TETANIA
  • 15.  
  • 16. Figure 24-27 Hormone production in pancreatic islet cells. Immunoperoxidase staining shows a dark reaction product for insulin in b cells (A), glucagon in a cells (B), and somatostatin in d cells (C). D, Electron micrograph of a b cell shows the characteristic membrane-bound granules, each containing a dense, often rectangular core and distinct halo. E, Portions of an a cell (left) and a d cell (right) also exhibit granules, but with closely apportioned membranes. The a-cell granule exhibits a dense, round center. (Electron micrographs courtesy of Dr. A. Like, University of Massachusetts Medical School, Worcester, MA.)
  • 17. Figure 24-28 Insulin synthesis and secretion. Intracellular transport of glucose is mediated by GLUT-2, an insulin-independent glucose transporter in b cells. Glucose undergoes oxidative metabolism in the b cell to yield ATP. ATP inhibits an inward rectifying potassium channel receptor on the b-cell surface; the receptor itself is a dimeric complex of the sulfonylurea receptor and a K+ -channel protein. Inhibition of this receptor leads to membrane depolarization, influx of Ca2+ ions, and release of stored insulin from b cells. Figure 24-29 Metabolic actions of insulin in striated muscle, adipose tissue, and liver.
  • 18. Figure 24-30 Insulin action on a target cell. Insulin binds to the a subunit of insulin receptor, leading to activation of the kinase activity in the b-subunit, and sets in motion a phosphorylation (i.e., activation) cascade of multiple downstream target proteins. The mitogenic functions of insulin (and the related insulin-like growth factors) are mediated via the mitogen-activated protein kinase (MAP kinase) pathway. The metabolic actions of insulin are mediated primarily by activation of the phosphatidylinositol-3-kinase (PI-3K) pathway. The PI-3K-signaling pathway is responsible for a variety of effects on target cells, including translocation of GLUT-4 containing vesicles to the surface; increasing GLUT-4 density on the membrane and rate of glucose influx; promoting glycogen synthesis via activation of glycogen synthase; and promoting protein synthesis and lipogenesis, while inhibiting lipolysis. The PI-3K pathway also promotes cell survival and proliferation.
  • 19. TABLE 24-6 -- Classification of Diabetes Mellitus •••••• Neoplasia •••••• Cystic fibrosis •••••• Hemachromatosis •••••• Fibrocalculous pancreatopathy •••••• Pancreatectomy •••••• Chronic pancreatitis • 5. Exocrine pancreatic defects •••••• Insulin receptor mutations •••••• Insulin gene mutations •••••• Defects in proinsulin conversion • 4. Genetic defects in insulin processing or insulin action •••••• Mitochondrial DNA mutations ••••••• Neurogenic differentiation factor 1 [Neuro D1] (MODY6) ••••••• Hepatocyte nuclear factor 1b [HNF-1b] (MODY5) ••••••• Insulin promoter factor [IPF-1] (MODY4) ••••••• Hepatocyte nuclear factor 1a [HNF-1a] (MODY3) ••••••• Glucokinase (MODY2) ••••••• Hepatocyte nuclear factor 4a [HNF-4a] (MODY1) •••••• Maturity-onset diabetes of the young (MODY), caused by mutations in: • 3. Genetic defects of b -cell function • 2. Type 2 diabetes (insulin resistance with relative insulin deficiency) •••••• Idiopathic •••••• Immune-mediated • 1. Type 1 diabetes (b-cell destruction, leads to absolute insulin deficiency)
  • 20. Data from the Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetic Care 25 (suppl. 1):S5–S20, 2002. 10. Gestational diabetes mellitus •••••• Turner syndrome •••••• Kleinfelter syndrome •••••• Down syndrome • 9. Genetic syndromes associated with diabetes •••••• Phenytoin •••••• Nicotinic acid •••••• Thiazides •••••• b-adrenergic agonists •••••• Protease inhibitors •••••• a-interferon •••••• Thyroid hormone •••••• Glucocorticoids • 8. Drugs •••••• Coxsackie virus B •••••• Cytomegalovirus • 7. Infections •••••• Glucagonoma •••••• Pheochromocytoma •••••• Hyperthyroidism •••••• Cushing syndrome •••••• Acromegaly • 6. Endocrinopathies
  • 21. Figure 24-31 Stages in the development of type 1 diabetes mellitus. The stages are listed from left to right, and hypothetical b-cell mass is plotted against age. (From Eisenbarth GE: Type 1 diabetes: a chronic autoimmune disease. N Engl J Med 314:1360, 1986. Copyright © 1986, Massachusetts Medical Society. All rights reserved.)
  • 22. Figure 24-33 Obesity and insulin resistance: the missing links? Adipocytes release a variety of factors (free fatty acids and adipokines) that may play a role in modulating insulin resistance in peripheral tissues (illustrated here is striated muscle). Excess free fatty acids (FFAs) and resistin are associated with insulin resistance; in contrast, adiponectin, whose levels are decreased in obesity, is an insulin-sensitizing adipokine. Leptin is also an insulin-sensitizing agent, but it acts via central receptors (in the hypothalamus). The peroxisome proliferator-activated receptor gamma (PPARg) is an adipocyte nuclear receptor that is activated by a class of insulin-sensitizing drugs called thiazolidinediones (TZDs). The mechanism of action of TZDs may eventually be mediated through modulation of adipokine and FFA levels that favor a state of insulin sensitivity.
  • 23. Figure 24-34 Long-term complications of diabetes.
  • 24. Figure 24-40 Sequence of metabolic derangements leading to diabetic coma in type 1 diabetes mellitus. An absolute insulin deficiency leads to a catabolic state, eventuating in ketoacidosis and severe volume depletion. These cause sufficient central nervous system compromise to lead to coma and eventual death if left untreated.
  • 25. TABLE 24-8 -- Type 1 Versus Type 2 Diabetes Mellitus (DM) Mild b-cell depletion b-cell depletion atrophy and amyloid deposition Marked atrophy and fibrosis Focal No insulitis Insulitis early Islet cells Absolute insulin deficiency b-cell dysfunction and relative insulin deficiency Insulin resistance in skeletal muscle, adipose tissue and liver Autoimmune destruction of b-cells mediated by T cells and humoral mediators (TNF, IL-1, NO) Pathogenesis Linkage to candidate diabetogenic genes (PPARg, calpain 10) No HLA linkage Linkage to MHC Class II HLA genes 50–90% concordance in twins 30–70% concordance in twins Genetics Ketoacidosis rare; nonketotic hyperosmolar coma Ketoacidosis common No anti-islet cell antibodies Anti-islet cell antibodies Increased blood insulin early); normal to moderate decreased insulin (late) Markedly decreased blood insulin Obese Normal weight Onset: >30 years <20 years Clinical Onset: Type 2 DM Type 1 DM